Sysmex Europe

The National Cancer Center, the National Center for Global Health and Medicine, and Sysmex Corporation Evaluatea SARS-CoV-2 Antibody Test with Support from the Japan Health Research Promotion Bureau

Performance Report onan Antibody Detection Reagent Using Clinical Specimens

The National Cancer Center (Location: Tokyo, Japan; President: Hitoshi Nakagama; “NCC”), the National Center for Global Health and Medicine (Location: Tokyo, Japan; President: Norihiro Kokudo; “NCGM”), and Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) are conducting joint research related to an antigen/antibody test for SARS-CoV-2, the virus that causes novel coronavirus (COVID-19). The entities hereby provide an overview of these activities and results of clinical evaluationsof antibody tests. The Japan Health Research Promotion Bureau (JH) supportsthisresearch project throughthe NCC and NCGM.

COVID-19, an  infectious  disease caused  when  SARS-CoV-2 sneak  intothe  body,  is  highly contagious,symptoms can worsen rapidly, and itis believed that many carriers are asymptomatic.   6.9 million people all over the world have been infected with the disease, 400,000 died,Japan has confirmed 17,000 infections and 900 deaths as of June 8, 2020.1 Currently, the first infectious wave of COVID-19 is converging in Japan, but the infection spread of the successively second wave, the third wave is expected. In preparation for the expected resurgence of COVID-19, we recognize the urgent need to establish a new testing methodology effective throughout from immediately after infection to the treatment and recovery period.

In May 2020, NCC, NCGM, and Sysmex began joint research,clinical evaluations related to an antigen/antibody testing method for SARS-CoV-2. NCC and NCGM providethe samples, and advice on test method development with clinical expertise.Meanwhile, Sysmex is using chemiluminescence enzyme immunoassay to develop diagnostic reagents to detect antigens present in nasopharyngeal mucus  and  antibodies  in  the  blood  (IgM,  IgG).  Sysmex also measures and  analyzes clinical performance, using the samples provided by the two centers. The newly established Japan Health Research Promotion Bureau (JH) is assisting this joint research by offering diagnostic support and assistance towardsmedical implementation.

The antibody detection reagents Sysmex has developed are used in conjunction with the in-housefully automated immunoassay system. The reagents detect individual antibodies (IgG, IgM) that react specifically with nucleocapsid protein2 (N antigen) and spike protein3 (S antigen). 

Using these reagents,concentrations of IgG antibodies against circulating N antigens and S antigens ina SARS-CoV-2 negative group and a group of SARS-CoV-2 patients upon hospital discharge were compared. Figure 1 shows a clear rise in antibody titersin the patient group, compared with the negative  group.  Sysmex  believes  these  detection  reagents  can  be  used  in a broadrange  ofepidemiological  research,  vaccine effect monitoring, and  other  clinical  applications, providing  a foundation for futuredevelopment of treatments.

In preparation for an expected resurgence of COVID-19, NCC, NCGM and Sysmex work together expediently establishing a testing method for clinical application, and contributing to diagnosis and treatment of COVID-19.

Sysmex’s Efforts Regarding COVID-19

As  a  manufacturer  of  clinical  testing  instruments  and  reagents,  Sysmex  supports  ongoing clinical testing conducted in healthcare settings around the world. We believe it is our mission to work alongside healthcare professionals to do everything in our power to prevent the spread of COVID-19 and overcome this crisis. To this end, we are doing our utmost to ensure a stable supply of products and services. Furthermore, we are engaged in initiatives to help prevent COVID-19 from spreading and to allow conditions to return to normal as quickly as possible. On this front, we have obtained the first regulatory approval in Japan for a novel coronavirus testing kit (RT-PCR method). We are leading Japan in collaboration between industry and the public sector  (the  city of Kobe) to enhance the PCR testing system. In addition, we are working proactively to develop new diagnostic technologies.

About the Japan Health Research Promotion Bureau (JH)

Six national R&D centers (NCC, NCGM, the National Cerebral and Cardiovascular Center, the National Center of Neurology and Psychiatry, the National Center for Child Health and Development, and the National Center for Geriatrics and Gerontology) conduct studies, research, and technical development related to advanced medicine. In April 2020, the Ministry of Health, Labour and Welfare and the six centers launched the Medical Research Promotion Division, National Research Center Specializing in Advanced Medicine (JH) to accelerate groundbreaking R&D related to clinical practice. JH decided to support R&D addressing SARS-CoV-2 swiftly and effectively,providing research and clinical testing support to companies participating in this project


1 From the “WKC’s new webpage with WHO official information on COVID-19 in Japanese” (As of June 8, 2020)

2 Nucleocapsid protein (N antigen):A protein that constitutes the core structure of a virus, significantly affecting virus characteristics.

3 Spike protein (S antigen):A protein that forms countless protrusions around the virus to bind with cell receptors causinginfection.

Back to overview



Copyright © Sysmex Europe SE. All rights reserved.
Customize your experience

We use cookies to enable you to optimally use our Website and to improve our communication with you. We shall take your selection into account and use only the data for which you give us your consent.

* May lead to restrictions in content and in the user experience
Detail about cookies
Essential cookies
These cookies help to make our website usable by enabling basic features such as page navigation and access to secure areas of our website. Our website cannot function properly without these cookies.
Statistics cookies
By collecting information anonymously, these cookies help us to understand how visitors interact with our website. This information enables us to continually improve our platform.
Marketing cookies
are used to track visitors on websites. The intention is to show advertisements that are relevant and appealing to the individual user and are, therefore, valuable to publishers and third-party advertisers.